Every material Form 8-K Xenetic Biosciences, Inc. has filed with the SEC since August 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xenetic Biosciences furnished an updated September 2026 investor presentation tied to its pending share exchange with Santersus AG, first announced September 16, 2026. The presentation shows Santersus shareholders expected to own about 85% of the combined company and Xenetic stockholders about 15%, subject to adjustment, with closing expected in the fourth quarter of 2026.
Transaction valuation shown as $120 million for Santersus and $21 million for Xenetic, or $141 million in total, under the Share Exchange Agreement dated September 14, 2026
Closing is expected in the fourth quarter of 2026 and is subject to approval by Xenetic stockholders
The combined company is expected to trade on Nasdaq under the ticker SNTS
Xenetic Biosciences agreed on September 14, 2026 to acquire all share capital of Swiss company Santersus AG in exchange for newly issued Xenetic common stock, subject to Xenetic stockholder approval and other conditions. On a pro forma basis, existing Xenetic equity holders would own about 15.0% of the combined company and Santersus equity holders about 85.0%, subject to adjustment based on Xenetic's net cash at closing, so current shareholders' stake would be substantially diluted.
Santersus equity holders expected to own about 85.0% and Xenetic equity holders about 15.0% of the combined company on a fully diluted basis.
Closing is expected in the fourth quarter of 2026, subject to stockholder approval, Nasdaq listing approval and an effective Form S-1 resale registration statement.
Xenetic may owe Santersus a $500,000 termination fee under specified circumstances; either party may reimburse the other for fees and expenses up to $300,000.
The combined company would be renamed Santersus Bio, Inc. with an eight-member board, six designated by Santersus, and expected to trade under the symbol SNTS.
Xenetic Biosciences reported results for the quarter ended June 30, 2026. Royalty revenue rose about 12% to about $0.7 million, but the net loss widened to about $0.9 million from about $0.7 million, mainly because general and administrative expenses rose about 64% on higher legal costs tied to its strategic review. Cash and cash equivalents fell to about $6.5 million from about $7.9 million at December 31, 2025.
Royalty revenue was about $0.7 million, up from about $0.6 million, primarily from the Takeda sublicense agreement
General and administrative expenses were about $1.1 million, up about 64%, mainly on higher legal expenses tied to the strategic review
Research and development expenses fell about 16% to about $0.6 million, mainly on lower manufacturing development efforts and reduced consulting costs
Cash and cash equivalents were about $6.5 million at June 30, 2026, versus about $7.9 million at December 31, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xenetic Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →